Skip to main content

Advertisement

Table 1 Baseline demographics and disease characteristics

From: Clinical efficacy and IL-17 targeting mechanism of Indigo naturalis as a topical agent in moderate psoriasis

  Placebo Indigo naturalis Total
Patients randomized, n 8 16 24
Men, n (%) 7 (87.5) 10 (62.5) 17 (70.8)
Race, n (%)
 Asian 8 (100) 16 (100) 24 (100)
Age, years 40.1 ± 10.9 39.3 ± 10.1 39.6 ± 10.1
Weight, kg 74.1 ± 16.7 73.2 ± 16.0 73.5 ± 15.9
Body mass index (kg/m2) 25.2 ± 4.6 25.9 ± 3.9 25.7 ± 4.0
Duration of psoriasis, years 14.9 ± 12.1 13.1 ± 11.1 13.7 ± 11.2
Age at diagnosis, years 25.3 ± 13.3 26.2 ± 12.0 25.7 ± 11.2
BSA involvement (%), 9.6 ± 5.8 8.4 ± 5.8 8.8 ± 5.7
PASI score (0–72) 11.1 ± 3.7 10.1 ± 4.3 10.4 ± 4.0
 ≥ 10, n (%) 4 (50.0) 8 (50.0) 12 (50.0)
 < 10, n (%) 4 (50.0) 8 (50.0) 12 (50.0)
PGA score 3.3 ± 0.5 3.0 ± 0.5 3.1 ± 0.5
OTPSS 3.8 ± 0.5 3.6 ± 0.5 3.6 ± 0.5
  1. Values are mean ± SD, unless otherwise indicated
  2. BSA body surface area, OTPSS Overall Target Plaque Severity Score, PASI Psoriasis Area and Severity Index, PGA Physician's Global Assessment, SD standard deviation